Jeff Johnson
Stock Analyst at Baird
(4.65)
# 201
Out of 5,044 analysts
148
Total ratings
58.42%
Success rate
29.07%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $68.18 | +32.00% | 15 | Sep 26, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $97 → $85 | $69.58 | +22.16% | 18 | Aug 28, 2025 | |
| ALC Alcon | Maintains: Outperform | $108 → $95 | $73.60 | +29.08% | 10 | Aug 21, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $26.79 | -36.54% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $62.32 | +15.53% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $19.98 | +15.12% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $99.71 | +15.33% | 14 | May 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $15.15 | +58.42% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $369.59 | +9.58% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $131.91 | +109.23% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $316.17 | -24.72% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $31.99 | +118.82% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.92 | +308.85% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $12.86 | +421.00% | 6 | Feb 18, 2022 |
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $68.18
Upside: +32.00%
The Cooper Companies
Aug 28, 2025
Maintains: Outperform
Price Target: $97 → $85
Current: $69.58
Upside: +22.16%
Alcon
Aug 21, 2025
Maintains: Outperform
Price Target: $108 → $95
Current: $73.60
Upside: +29.08%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $26.79
Upside: -36.54%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $62.32
Upside: +15.53%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $19.98
Upside: +15.12%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $99.71
Upside: +15.33%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $15.15
Upside: +58.42%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $369.59
Upside: +9.58%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $131.91
Upside: +109.23%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $316.17
Upside: -24.72%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $31.99
Upside: +118.82%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.92
Upside: +308.85%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $12.86
Upside: +421.00%